Dr. Lal PathLabs Limited records revenue of Rs 606.6 Cr in Q1 FY 2021-22

Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2021.

• Operating Revenue increased by 128.1% in Q1 FY22 to Rs. 606.6 Cr vs Rs 266.0 Cr in Q1 FY21
• Covid and Allied contributed 36.4% to Revenue in Q1 FY22 with 11.4 lac RTPCR tests
• Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q1 FY22 is at Rs. 199.0 Cr Vs Rs 54.0 Cr in the same quarter last year
• PBT is at Rs 179.3 Cr in Q1 FY22 vs Rs 38.1 Cr. in Q1 last year
• Profit after Tax in Q1 FY22 at Rs. 133.7 Cr as compared to Rs 28.4 Cr in Q1 last year
• Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

MB Bureau